Anika Therapeutics (ANIK) reported second-quarter 2026 revenue of $32.6 million, up 16% from $28.2 million a year earlier. Commercial Channel revenue rose 17% to a record $13.9 million, while OEM Channel revenue increased 14% to $18.7 million.
The company reported net income of $3.3 million, or $0.24 per diluted share from continuing operations, and adjusted EBITDA of $7.1 million. Anika raised its 2026 revenue growth guidance and adjusted EBITDA margin outlook, and revised its 2027 revenue forecast to include only products with regulatory approval or clearance.
- Gross profit was $21.2 million and gross margin was 65%.
- Operating expenses were $18.3 million, compared with $18.5 million in the prior-year period.
- International revenue reached a record $12.6 million, up 22% year over year.
- Updated 2026 total company revenue guidance calls for 5% to 10% growth, and adjusted EBITDA margin guidance is 13% to 17%.
- 2027 Commercial Channel revenue growth guidance was revised to 5% to 15%, while total company revenue guidance is flat to 5% growth.
$ANIK Insider Trading Activity
$ANIK insiders have traded $ANIK stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ANIK stock by insiders over the last 6 months:
- STEPHEN D. GRIFFIN (President and CEO) purchased 12,200 shares for an estimated $149,880
- JOHN B III HENNEMAN purchased 5,000 shares for an estimated $73,319
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ANIK Hedge Fund Activity
We have seen 65 institutional investors add shares of $ANIK stock to their portfolio, and 46 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEUTSCHE BANK AG\ added 271,884 shares (+334.5%) to their portfolio in Q1 2026, for an estimated $3,942,318
- AQR CAPITAL MANAGEMENT LLC added 202,989 shares (+293.0%) to their portfolio in Q1 2026, for an estimated $2,943,340
- TRIGRAN INVESTMENTS, INC. removed 168,400 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,441,800
- UBS GROUP AG added 104,529 shares (+366.2%) to their portfolio in Q1 2026, for an estimated $1,515,670
- MORGAN STANLEY added 99,836 shares (+12.9%) to their portfolio in Q1 2026, for an estimated $1,447,622
- JEFFERIES FINANCIAL GROUP INC. added 93,500 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,355,750
- JANE STREET GROUP, LLC removed 80,344 shares (-59.6%) from their portfolio in Q1 2026, for an estimated $1,164,988
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
